Early detection and new biomarkers are changing how we manage acute kidney injury—and its link to chronic kidney disease.

1 Lupus nephritis (LN) is one of the most severe forms of organ ... and disease subtyping but also lay the foundation for a deeper understanding of LN pathophysiology. Moreover, through the deep ...

Among the independent risk factors for excess mortality, CKD is still one of the strongest predictors of a poor prognosis in patients with both ANCA- associated vasculitis (AAV) and lupus nephritis ..

The American College of Rheumatology last published recommendations for managing lupus nephritis (LN) in 2012. Since then, targeted treatments including belimumab (Benlysta) and voclosporin ...

Following is the complete guide to Aurinia's accepted abstracts at LUPUS 2025: Title: Achievement of Proteinuria Less Than 0.4 G/G in the Phase 3 AURORA 1 Study of Voclosporin in Lupus Nephritis ...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today announced that a post-hoc analysis of the 52-week, Phase 3 AURORA 1 study showed that lupus nephritis (LN) patients who ...

It is the only clinical program in lupus nephritis to include three years of triple immunosuppressive therapy. LUPKYNIS is indicated in combination with a background immunosuppressive therapy ...

The US regulator has started a review of Roche's supplemental biologics license application (BLA) for Gazyva/Gazyvaro (obinutuzumab) as a treatment for lupus nephritis, with a decision expected in ...

A multidisciplinary, multi-organizational panel of experts in medical oncology, dermatology, gastroenterology, rheumatology, pulmonology, endocrinology, urology ...

Despite its flawed safety and efficacy, cyclophosphamide remains the standard therapy for severe lupus nephritis. Mycophenolate mofetil shows promise as an alternative. To determine whether ...